Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Theabrownin is a complex, water-soluble phenolic pigment and a primary bioactive component found in fermented teas, most notably Pu-erh tea. It is formed during the fermentation process through the oxidative polymerization of polyphenols like catechins, theaflavins, and thearubigins. Theabrownin has demonstrated various pharmacological activities, including anti-tumor, anti-obesity, cholesterol-lowering, and blood glucose-regulating effects. In the context of oncology, it has been shown to inhibit the proliferation and induce apoptosis of hepatocellular carcinoma cells by activating the c-Jun N-terminal kinase (JNK) signaling pathway and modulating the expression of pro-apoptotic (Bax, Bim, PUMA) and anti-apoptotic (Bcl-2) proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on theabrownin.